EDITORIAL
Published on 19 Apr 2024
Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment
doi 10.3389/fonc.2024.1411836
- 575 views
- Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
- Research Topics
- Emerging Anti-cancer Compounds and Immunomodulators for Pancreatic Cancer Treatment
Emerging Anti-cancer Compounds and Immunomodulators for Pancreatic Cancer Treatment
6,849
Total downloads
34k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
REVIEW
Published on 06 Mar 2024
Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer
doi 10.3389/fonc.2024.1371421
- 4,331 views
- 1 citation
MINI REVIEW
Published on 04 Mar 2024
The TGF-β superfamily as potential therapeutic targets in pancreatic cancer
doi 10.3389/fonc.2024.1362247
- 2,093 views
REVIEW
Published on 21 Feb 2024
Exploring the application and future outlook of Artificial intelligence in pancreatic cancer
doi 10.3389/fonc.2024.1345810
- 1,966 views
- 5 citations
SYSTEMATIC REVIEW
Published on 08 Feb 2024
Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta-analysis
doi 10.3389/fonc.2024.1331706
- 758 views
- 2 citations
ORIGINAL RESEARCH
Published on 27 Oct 2023
PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study
doi 10.3389/fonc.2023.1281545
- 1,449 views
- 1 citation
ORIGINAL RESEARCH
Published on 21 Sep 2023
Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
doi 10.3389/fonc.2023.1251258
- 2,733 views
- 1 citation
MINI REVIEW
Published on 16 Mar 2023
Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies
doi 10.3389/fonc.2023.1138759
- 32,094 views
- 9 citations
ORIGINAL RESEARCH
Published on 14 Mar 2023
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma
doi 10.3389/fonc.2023.1140730
- 3,413 views
- 10 citations
ORIGINAL RESEARCH
Published on 05 Oct 2022
Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteosome assembly
doi 10.3389/fonc.2022.870473
- 1,369 views
- 1 citation
Published in
Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
Participating Journals
Frontiers in Pharmacology
Cancer Molecular Targets and TherapeuticsOffline
- 4.4 impact factor
- 7.8 citescore
Impact
- 34kTopic views
- 22kArticle views
- 6,849Article downloads